Shanghai Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Ruiji Biological.

Shanghai Haohai Biological Technology (688366.SH) announced that the company plans to use its own funds of RMB 38.3515 million to acquire a total of 8.4661 million shares of Jiangxi Ruiji Biotechnology Co., Ltd. (hereinafter referred to as "Ruiji Biotechnology"), representing 19.8% of Ruiji Biotechnology's total share capital. Ruiji Biotechnology was established in 2002 and its main business is the production and sale of biological amniotic membrane products. Its main products and services include concave and convex amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, which are classified as Class III medical devices in China. These products are mainly used in the fields of orthopedics and ophthalmology for purposes such as repairing tendon injuries, treating burns and wounds on the surface of the eye, implantation and support after lacrimal duct unblocking. By investing in the target company and obtaining distribution rights for its products in China, the company aims to enter the high-value medical device market for biological amniotic membrane products, supplement its existing product portfolio, and expand its business coverage in the ophthalmology and orthopedic fields. Additionally, the amniotic membrane materials held by the target company have important human biological characteristics, providing a technical and material basis for the company's research and development in the fields of regenerative medicine and tissue engineering, which is expected to drive product innovation and technological upgrades in the future.